The "Hepcidin Antagonist -Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

'Hepcidin Antagonist - Pipeline Insight, 2018' report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Hepcidin Antagonist development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Descriptive coverage of pipeline development activities for Hepcidin Antagonist - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Key Topics Covered:

1. Report Introduction

2. Hepcidin Antagonist - Overview

3. Pipeline Therapeutics

• An Overview of Pipeline Products for Hepcidin Antagonist

4. Comparative Analysis

5. Hepcidin Antagonist Pipeline Products in Clinical Stages

• Product Description
• Research and Development
• Product Development Activities

6. Hepcidin Antagonist Pipeline Products in Non-clinical Stages

• Product Description
• Research and Development
• Product Development Activities

Other product profiles in the detailed report.

7. Therapeutic Assessment: Active Products

• Pipeline Assessment by Route of Administration
• Pipeline Assessment by Stage and Route of Administration
• Pipeline Assessment by Molecule Type
• Pipeline Assessment by Stage and Molecule Type

8. Inactive Pipeline Products

• Product Description
• Research and Development
• Product Development Activities
• Reason for dormancy/discontinuation

Companies Mentioned

• Pieris Pharmaceuticals
• Alnylam Pharmaceuticals
• FerruMax Pharmaceuticals
• Isis Pharmaceuticals
• Tolero Pharmaceuticals

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/bbpgrs/hepcidin?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20181213005927/en/